Voyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Down 17.3% in November

Voyager Therapeutics, Inc. (NASDAQ:VYGR) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,440,000 shares, a decrease of 17.3% from the October 31st total of 2,950,000 shares. Based on an average daily volume of 562,900 shares, the short-interest ratio is currently 4.3 days.

Wall Street Analyst Weigh In

Several analysts have weighed in on VYGR shares. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 18th. Wedbush assumed coverage on Voyager Therapeutics in a research note on Friday. They issued an “outperform” rating and a $11.00 price target on the stock. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners began coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $17.50.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. American International Group Inc. raised its position in shares of Voyager Therapeutics by 22.9% during the first quarter. American International Group Inc. now owns 19,397 shares of the company’s stock valued at $181,000 after buying an additional 3,610 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Voyager Therapeutics by 95.3% in the first quarter. Lazard Asset Management LLC now owns 18,742 shares of the company’s stock worth $174,000 after buying an additional 9,146 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after acquiring an additional 37,144 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter worth $85,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Price Performance

VYGR stock opened at $6.86 on Friday. Voyager Therapeutics has a 1 year low of $5.19 and a 1 year high of $11.72. The company has a market cap of $374.76 million, a P/E ratio of 9.66 and a beta of 0.89. The stock’s fifty day moving average price is $6.51 and its 200-day moving average price is $7.31.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted ($0.59) earnings per share. As a group, analysts expect that Voyager Therapeutics will post -1.03 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.